Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cugno

Showing results (21-30 of 147) with videos related to

Pageof 15
Sort By:
JAMA Dermatology|January 26, 2022
Venous Thromboembolism in Chronic Inflammatory Skin Diseases-The Need to Consider Bullous PemphigoidAngelo Valerio Marzano, Giovanni Genovese, Massimo Cugno
European Journal of Internal Medicine|December 18, 2015
Adverse drug reactions and organ damage: The skinAngelo V Marzano, Alessandro Borghi, Massimo Cugno
American Journal of Clinical Dermatology|February 26, 2017
PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and TreatmentMassimo Cugno, Alessandro Borghi, Angelo V Marzano
Frontiers in Immunology|October 26, 2019
Editorial: Neutrophil-Mediated Skin Diseases: Immunology and GeneticsAngelo V Marzano, Dan Lipsker, Massimo Cugno
The Journal of Allergy and Clinical Immunology|May 6, 2006
Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serumRiccardo Asero, Alberto Tedeschi, Piersandro Riboldi, et al.
Critical Reviews in Oncology/Hematology|March 16, 2013
Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationshipRoberto Castelli, Andrea Zanichelli, Marco Cicardi, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2012
Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromesRoberto Castelli, Ramona Cassin, Antonino Cannavò, et al.
Expert Review of Clinical Immunology|October 20, 2022
Biologics for chronic spontaneous urticaria: toward a personalized treatmentRiccardo Asero, Silvia Ferrucci, Alberto Tedeschi, et al.
Current Vascular Pharmacology|June 3, 2009
Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritisMassimo Cugno, Francesca Ingegnoli, Roberta Gualtierotti, et al.
International Immunopharmacology|March 18, 2003
Bradykinin and the pathophysiology of angioedemaMassimo Cugno, Jürg Nussberger, Marco Cicardi, et al.
Pageof 15

Showing results (21-30 of 147) with videos related to

Sort By:
Pageof 15
JAMA Dermatology|January 26, 2022
Venous Thromboembolism in Chronic Inflammatory Skin Diseases-The Need to Consider Bullous PemphigoidAngelo Valerio Marzano, Giovanni Genovese, Massimo Cugno
European Journal of Internal Medicine|December 18, 2015
Adverse drug reactions and organ damage: The skinAngelo V Marzano, Alessandro Borghi, Massimo Cugno
American Journal of Clinical Dermatology|February 26, 2017
PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and TreatmentMassimo Cugno, Alessandro Borghi, Angelo V Marzano
Frontiers in Immunology|October 26, 2019
Editorial: Neutrophil-Mediated Skin Diseases: Immunology and GeneticsAngelo V Marzano, Dan Lipsker, Massimo Cugno
The Journal of Allergy and Clinical Immunology|May 6, 2006
Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serumRiccardo Asero, Alberto Tedeschi, Piersandro Riboldi, et al.
Critical Reviews in Oncology/Hematology|March 16, 2013
Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationshipRoberto Castelli, Andrea Zanichelli, Marco Cicardi, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 17, 2012
Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromesRoberto Castelli, Ramona Cassin, Antonino Cannavò, et al.
Expert Review of Clinical Immunology|October 20, 2022
Biologics for chronic spontaneous urticaria: toward a personalized treatmentRiccardo Asero, Silvia Ferrucci, Alberto Tedeschi, et al.
Current Vascular Pharmacology|June 3, 2009
Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritisMassimo Cugno, Francesca Ingegnoli, Roberta Gualtierotti, et al.
International Immunopharmacology|March 18, 2003
Bradykinin and the pathophysiology of angioedemaMassimo Cugno, Jürg Nussberger, Marco Cicardi, et al.
Pageof 15